Pediatric Pulmonary Hypertension

Abstract

Abstract-Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of consensus guidelines from experts in the field. In a joint effort from the American Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. Key Words: AHA Scientific Statements ◼ bronchopulmonary dysplasia ◼ congenital diaphragmatic hernia ◼ congenital heart disease ◼ genetics ◼ persistent pulmonary hypertension of the newborn ◼ sickle cell disease © 2015 by the American Heart Association, Inc., and the American Thoracic Society.Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000329 †Deceased. The American Heart Association and the American Thoracic Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This document was approved by the American Heart Association Science Advisory and Coordinating Committee on May 12, 2015, the American Heart Association Executive Committee on July 22, 2015, and the American Thoracic Society on July 24, 2015.The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000329/-/DC1. The American Heart Association requests that this document be cited as follows: Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037-2099 Copies: This document is available on the World Wide Web site of the American Heart Associat...

The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension

“…This notion is supported by longitudinal studies that identified PA stiffness as a highly significant (P , 0.001) predictor of mortality in a cohort of 86 patients with pulmonary arterial hypertension (PAH) during a follow-up of 48 months (5). In addition to its…”

“…Although this may likely represent a confounding effect or a common causality of these clinical parameters on the relationship of HDGF and outcome as the authors suggest, this also limits the additive clinical benefit of HDGF measurement in predicting outcome, as these measures are already obtained as part of routine clinical practice. In PAH, there is an important need for biomarkers or other noninvasive measures that reliably predict invasive hemodynamics to limit the need for serial cardiac catheterizations, with the attendant risk for morbidity and mortality (5). From the authors' analysis, HDGF does not appear to meet this need.…”

El rol de la hipertensión pulmonar en la displasia broncopulmonar

“…Por otro lado, la cateterización cardíaca permite también la detección de lesiones como estenosis de vena pulmonar y colaterales que pueden presentarse en DBP, pero que no son fáciles de diagnosticar mediante ecografía. Es por esto que las guías de Hipertensión Pulmonar publicadas por la American Heart Association recomienda considerar el cateterismo cardiaco en algunos casos específicos como: 1) signos persistentes de enfermedad cardiorrespiratoria severa o deterioro clínico no explicado directamente por otra evaluación diagnóstica; 2) sospecha de tener HP significativa a pesar de manejo óptimo; 3) consideración de terapia vasodilatadora crónica; 4) presentación de edema pulmonar recurrente inexplicado 7,12 .…”

“…Prostanoides de uso sistémico como epoporostenol han sido usado en algunas series, pero causan hipotensión sistémica lo que limita su uso. Con la evidencia disponible en niños, las guías clínicas de la AHA para la HP del 2015 concluyen que los usos de estas terapias específicas pueden ser útiles cuando se han manejado todas las causas subyacentes tanto pulmonares como cardía-cas 12 . En nuestro centro empleamos habitualmente inicio de tratamiento con sildenafil como primera lí-nea cuando los pacientes presentan HP secundaria a DBP severa, luego de haber evaluado y tratado pertinentemente otras posibles etiologías subyacentes.…”

Pediatric and Adolescent Pulmonary Hypertension: What Is the Risk of Undergoing Invasive Hemodynamic Testing?

“…Hemodynamic assessment with HC is the standard tool used to evaluate hemodynamics at presentation and in reassessment after targeted therapy 3. The overall adverse event (AE) rate with pediatric HC is relatively low at 0.1%4; however, HC in children with PH is substantially higher, with cardiac arrest occurring in 4% to 6% 5, 6…”